An Indian-origin hedge fund manager was on June 15 charged by the Securities and Exchange Commission with insider trading after he reaped unlawful profits of nearly $32 million by trading on pharma stocks on the basis of tips he received from a former US government official.
Sanjay Valvani, 44, reaped unlawful profits of nearly $32 million for hedge funds investing in health care securities by insider trading on tips he received from Gordon Johnston, who worked at the Food and Drug Administration and deceptively obtained confidential information.
In parallel actions, the office of US Attorney for the Southern District of New York Preet Bharara also announced criminal charges against Valvani and Johnston.
- US: Indian-origin man pleads guilty to insider trading
- Rajat Gupta: Corporate climb,insider info
- Indian-American charged in biggest insider trading case in US
- Indian among 14 more charged in Wall St scam
- US poised to bring more insider trading cases
- Record insider-trading scam rocks Wall St,2 Indians in dock
In the criminal complaint, Valvani has been charged on five counts including securities fraud, defrauding the US and wire fraud.
The charges also carry a maximum fine of $5 million.
The Securities and Exchange Commission (SEC) alleges that Johnston concealed his separate role as a hedge fund consultant and obtained confidential information about anticipated FDA approvals for companies to produce enoxaparin, a generic drug that helps prevent formation of blood clots.
Johnston allegedly funneled to Valvani the details of his conversations with FDA personnel, including a close friend he mentored during his time at the agency.
Valvani then traded in advance of public announcements concerning FDA approvals for such companies as Momenta Pharmaceuticals, Watson Pharmaceuticals, and Amphastar Pharmaceuticals.
“We allege that Valvani’s formula for trading success was tapping Johnston to abuse his position of trust as a generic industry representative to the FDA and underhandedly obtain confidential information from his friends and former colleagues at the FDA,” said Andrew Ceresney, Director of the SEC’s Division of Enforcement.
Ceresney said Valvani and his hedge funds made millions by trading on non-public FDA drug approval information not available to the rest of the stock market.
The SEC further alleges that Valvani in turn tipped fellow hedge fund manager Christopher Plaford, who is charged in a separate complaint with insider trading on this non-public information.
Plaford allegedly made approximately USD 300,000 by trading based on inside information in hedge funds he managed.